Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit

A prescribing protocol for infective exacerbations of chronic obstructive airways disease (COAD), specifying the use of oral amoxycillin 500 mg tid (or erythromycin 500 mg qid if allergic) as first line therapy, and oral ciprofloxacin 500 mg bd as second line treatment, was introduced in 1991. Every...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of antimicrobial chemotherapy 1995-08, Vol.36 (2), p.403-409
Hauptverfasser: Boyter, A. C., Davey, P. G., Hudson, S. A., Clark, R. A., Lipwortn, B. J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 409
container_issue 2
container_start_page 403
container_title Journal of antimicrobial chemotherapy
container_volume 36
creator Boyter, A. C.
Davey, P. G.
Hudson, S. A.
Clark, R. A.
Lipwortn, B. J.
description A prescribing protocol for infective exacerbations of chronic obstructive airways disease (COAD), specifying the use of oral amoxycillin 500 mg tid (or erythromycin 500 mg qid if allergic) as first line therapy, and oral ciprofloxacin 500 mg bd as second line treatment, was introduced in 1991. Every third sequential admission was screened for the year preceding (1990) and the year after (1991) the protocol was implemented. Only those patients with a discharge diagnosis of infective exacerbation of COAD, but without pneumonia, were included in the analysis. The two groups (1990 and 1991) were matched in terms of age, sex and pre-treatment given by their General Practitioner (GP), but differed with respect to severity score, with 1991 being more severe. The outcome measures showed that duration of hospital stay was comparable as was duration of treatment. Response to first line therapy was 68% and 67% for 1990 and 1991, respectively. Of those who had received antibiotics from their GP, 67% responded to first line therapy, while of those who had not received antibiotics from their GP 75% responded. Duration of therapy was shorter in first line responders (mean and 95% CI: 7.3 (6.3–8.3) days vs 12.7 (10.1–15.3) days). The mean cost per day antibiotic treatment was reduced by 54.6% (95% CI 52.3–56.9%) from £3.77 to £1.71. In conclusion, the introduction of antibiotic prescribing guidelines for treatment of infective exacerbations of COAD showed no detrimental effect on outcome measures, but was associated with a significant reduction in the cost of antibiotic therapy.
doi_str_mv 10.1093/jac/36.2.403
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77649007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77649007</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-c675692668571c854d82d4f974234ec103a29044245fbdf7e5034d9c0ed2e9ef3</originalsourceid><addsrcrecordid>eNqFkU9vEzEQxVcIVELhxhXJB8SJTcf_d4-oaihSEZciRVwsr3eWumzWwfaW5rPwZXGaKFckS2PP-80bWa-q3lJYUmj5xb11F1wt2VIAf1YtqFBQM2jp82oBHGStheQvq1cp3QOAkqo5q84ayZjQsKj-Xj3YcbbZh4mEgdipnOw7H7J3ZBsxuVhe089yDzm4MJIhRJIj2rzBKT_NuDkjwUfrMHZPTmnfdncxTMUkdCnH2WX_gMT6-MfuEul9QpuQ-LKO3IW09dmOpGzb-mhziDsyTz6_rl4Mdkz45ljPq--rq9vL6_rm2-cvl59uaiegzbVTWqqWKdVITV0jRd-wXgytFowLdBS4ZS0IwYQcun7QKIGLvnWAPcMWB35efTj4lj_-njFls_HJ4TjaCcOcjNZKtAD6vyDVAJK2e_DjAXQxpBRxMNvoNzbuDAWzD82U0AxXhpkSWsHfHX3nboP9CT6mVPT3R90mZ8ch2sn5dMK4YpoqWrD6gPmU8fEk2_jLKM21NNfrH-Z2LVcr9VWYNf8HReOx7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17005197</pqid></control><display><type>article</type><title>Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit</title><source>MEDLINE</source><source>Oxford University Press Journals Archive</source><creator>Boyter, A. C. ; Davey, P. G. ; Hudson, S. A. ; Clark, R. A. ; Lipwortn, B. J.</creator><creatorcontrib>Boyter, A. C. ; Davey, P. G. ; Hudson, S. A. ; Clark, R. A. ; Lipwortn, B. J.</creatorcontrib><description>A prescribing protocol for infective exacerbations of chronic obstructive airways disease (COAD), specifying the use of oral amoxycillin 500 mg tid (or erythromycin 500 mg qid if allergic) as first line therapy, and oral ciprofloxacin 500 mg bd as second line treatment, was introduced in 1991. Every third sequential admission was screened for the year preceding (1990) and the year after (1991) the protocol was implemented. Only those patients with a discharge diagnosis of infective exacerbation of COAD, but without pneumonia, were included in the analysis. The two groups (1990 and 1991) were matched in terms of age, sex and pre-treatment given by their General Practitioner (GP), but differed with respect to severity score, with 1991 being more severe. The outcome measures showed that duration of hospital stay was comparable as was duration of treatment. Response to first line therapy was 68% and 67% for 1990 and 1991, respectively. Of those who had received antibiotics from their GP, 67% responded to first line therapy, while of those who had not received antibiotics from their GP 75% responded. Duration of therapy was shorter in first line responders (mean and 95% CI: 7.3 (6.3–8.3) days vs 12.7 (10.1–15.3) days). The mean cost per day antibiotic treatment was reduced by 54.6% (95% CI 52.3–56.9%) from £3.77 to £1.71. In conclusion, the introduction of antibiotic prescribing guidelines for treatment of infective exacerbations of COAD showed no detrimental effect on outcome measures, but was associated with a significant reduction in the cost of antibiotic therapy.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/36.2.403</identifier><identifier>PMID: 8522470</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - economics ; Anti-Bacterial Agents - therapeutic use ; Biological and medical sciences ; Chronic obstructive pulmonary disease, asthma ; Cost Savings ; Drug Prescriptions - economics ; Female ; Humans ; Length of Stay ; Lung Diseases, Obstructive - complications ; Lung Diseases, Obstructive - drug therapy ; Male ; Medical sciences ; Middle Aged ; Pneumology ; Respiratory Therapy Department, Hospital - economics ; Respiratory Therapy Department, Hospital - organization &amp; administration ; Treatment Outcome</subject><ispartof>Journal of antimicrobial chemotherapy, 1995-08, Vol.36 (2), p.403-409</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-c675692668571c854d82d4f974234ec103a29044245fbdf7e5034d9c0ed2e9ef3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3627161$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8522470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boyter, A. C.</creatorcontrib><creatorcontrib>Davey, P. G.</creatorcontrib><creatorcontrib>Hudson, S. A.</creatorcontrib><creatorcontrib>Clark, R. A.</creatorcontrib><creatorcontrib>Lipwortn, B. J.</creatorcontrib><title>Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>A prescribing protocol for infective exacerbations of chronic obstructive airways disease (COAD), specifying the use of oral amoxycillin 500 mg tid (or erythromycin 500 mg qid if allergic) as first line therapy, and oral ciprofloxacin 500 mg bd as second line treatment, was introduced in 1991. Every third sequential admission was screened for the year preceding (1990) and the year after (1991) the protocol was implemented. Only those patients with a discharge diagnosis of infective exacerbation of COAD, but without pneumonia, were included in the analysis. The two groups (1990 and 1991) were matched in terms of age, sex and pre-treatment given by their General Practitioner (GP), but differed with respect to severity score, with 1991 being more severe. The outcome measures showed that duration of hospital stay was comparable as was duration of treatment. Response to first line therapy was 68% and 67% for 1990 and 1991, respectively. Of those who had received antibiotics from their GP, 67% responded to first line therapy, while of those who had not received antibiotics from their GP 75% responded. Duration of therapy was shorter in first line responders (mean and 95% CI: 7.3 (6.3–8.3) days vs 12.7 (10.1–15.3) days). The mean cost per day antibiotic treatment was reduced by 54.6% (95% CI 52.3–56.9%) from £3.77 to £1.71. In conclusion, the introduction of antibiotic prescribing guidelines for treatment of infective exacerbations of COAD showed no detrimental effect on outcome measures, but was associated with a significant reduction in the cost of antibiotic therapy.</description><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - economics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Cost Savings</subject><subject>Drug Prescriptions - economics</subject><subject>Female</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Lung Diseases, Obstructive - complications</subject><subject>Lung Diseases, Obstructive - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><subject>Respiratory Therapy Department, Hospital - economics</subject><subject>Respiratory Therapy Department, Hospital - organization &amp; administration</subject><subject>Treatment Outcome</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9vEzEQxVcIVELhxhXJB8SJTcf_d4-oaihSEZciRVwsr3eWumzWwfaW5rPwZXGaKFckS2PP-80bWa-q3lJYUmj5xb11F1wt2VIAf1YtqFBQM2jp82oBHGStheQvq1cp3QOAkqo5q84ayZjQsKj-Xj3YcbbZh4mEgdipnOw7H7J3ZBsxuVhe089yDzm4MJIhRJIj2rzBKT_NuDkjwUfrMHZPTmnfdncxTMUkdCnH2WX_gMT6-MfuEul9QpuQ-LKO3IW09dmOpGzb-mhziDsyTz6_rl4Mdkz45ljPq--rq9vL6_rm2-cvl59uaiegzbVTWqqWKdVITV0jRd-wXgytFowLdBS4ZS0IwYQcun7QKIGLvnWAPcMWB35efTj4lj_-njFls_HJ4TjaCcOcjNZKtAD6vyDVAJK2e_DjAXQxpBRxMNvoNzbuDAWzD82U0AxXhpkSWsHfHX3nboP9CT6mVPT3R90mZ8ch2sn5dMK4YpoqWrD6gPmU8fEk2_jLKM21NNfrH-Z2LVcr9VWYNf8HReOx7A</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>Boyter, A. C.</creator><creator>Davey, P. G.</creator><creator>Hudson, S. A.</creator><creator>Clark, R. A.</creator><creator>Lipwortn, B. J.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit</title><author>Boyter, A. C. ; Davey, P. G. ; Hudson, S. A. ; Clark, R. A. ; Lipwortn, B. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-c675692668571c854d82d4f974234ec103a29044245fbdf7e5034d9c0ed2e9ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - economics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Cost Savings</topic><topic>Drug Prescriptions - economics</topic><topic>Female</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Lung Diseases, Obstructive - complications</topic><topic>Lung Diseases, Obstructive - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><topic>Respiratory Therapy Department, Hospital - economics</topic><topic>Respiratory Therapy Department, Hospital - organization &amp; administration</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boyter, A. C.</creatorcontrib><creatorcontrib>Davey, P. G.</creatorcontrib><creatorcontrib>Hudson, S. A.</creatorcontrib><creatorcontrib>Clark, R. A.</creatorcontrib><creatorcontrib>Lipwortn, B. J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boyter, A. C.</au><au>Davey, P. G.</au><au>Hudson, S. A.</au><au>Clark, R. A.</au><au>Lipwortn, B. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>36</volume><issue>2</issue><spage>403</spage><epage>409</epage><pages>403-409</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>A prescribing protocol for infective exacerbations of chronic obstructive airways disease (COAD), specifying the use of oral amoxycillin 500 mg tid (or erythromycin 500 mg qid if allergic) as first line therapy, and oral ciprofloxacin 500 mg bd as second line treatment, was introduced in 1991. Every third sequential admission was screened for the year preceding (1990) and the year after (1991) the protocol was implemented. Only those patients with a discharge diagnosis of infective exacerbation of COAD, but without pneumonia, were included in the analysis. The two groups (1990 and 1991) were matched in terms of age, sex and pre-treatment given by their General Practitioner (GP), but differed with respect to severity score, with 1991 being more severe. The outcome measures showed that duration of hospital stay was comparable as was duration of treatment. Response to first line therapy was 68% and 67% for 1990 and 1991, respectively. Of those who had received antibiotics from their GP, 67% responded to first line therapy, while of those who had not received antibiotics from their GP 75% responded. Duration of therapy was shorter in first line responders (mean and 95% CI: 7.3 (6.3–8.3) days vs 12.7 (10.1–15.3) days). The mean cost per day antibiotic treatment was reduced by 54.6% (95% CI 52.3–56.9%) from £3.77 to £1.71. In conclusion, the introduction of antibiotic prescribing guidelines for treatment of infective exacerbations of COAD showed no detrimental effect on outcome measures, but was associated with a significant reduction in the cost of antibiotic therapy.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>8522470</pmid><doi>10.1093/jac/36.2.403</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 1995-08, Vol.36 (2), p.403-409
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_77649007
source MEDLINE; Oxford University Press Journals Archive
subjects Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - economics
Anti-Bacterial Agents - therapeutic use
Biological and medical sciences
Chronic obstructive pulmonary disease, asthma
Cost Savings
Drug Prescriptions - economics
Female
Humans
Length of Stay
Lung Diseases, Obstructive - complications
Lung Diseases, Obstructive - drug therapy
Male
Medical sciences
Middle Aged
Pneumology
Respiratory Therapy Department, Hospital - economics
Respiratory Therapy Department, Hospital - organization & administration
Treatment Outcome
title Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A12%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20an%20antibiotic%20prescribing%20protocol%20for%20treatment%20of%20acute%20exacerbations%20of%20chronic%20obstructive%20airways%20disease%20in%20a%20hospital%20respiratory%20unit&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Boyter,%20A.%20C.&rft.date=1995-08-01&rft.volume=36&rft.issue=2&rft.spage=403&rft.epage=409&rft.pages=403-409&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/36.2.403&rft_dat=%3Cproquest_cross%3E77649007%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17005197&rft_id=info:pmid/8522470&rfr_iscdi=true